New York, NY – October 24, 2018 – Sichenzia Ross Ference LLP, announced today that it represented Wize Pharma, Inc. (OTCQB: “WIZP”), a clinical stage Israel based U.S. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common stock at $1.00 per share and 1,350 shares of newly created Series A preferred stock which is convertible at $1.00 per share.
The investors also received 100% 5 year Series A and 100% 6 month Series B warrants exercisable at $1.00 per share and $1.10 per share respectively. Wize received gross proceeds of $4.45 million.
The Sichenzia Ross Ference LLP team was led by Partner Gregory Sichenzia and Counsel Jeff Cahlon.
- Sichenzia Ross Ference Carmel LLP Represents Safe & Green Holdings Corp. in a $8.0 Million Private Placement - April 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents FatPipe, Inc. in Closing of $4 Million Initial Public Offering - April 10, 2025
- Sichenzia Ross Ference Carmel Names Matilde Tysz as Chief Strategy Officer - April 9, 2025
